Superseded public profile

FDA-approved↗Metabolic↗

Superseded · version 3: Semaglutide↗

Related names recorded in this version: Wegovy, Ozempic, Rybelsus↗

A GLP-1 receptor agonist. This profile cites a Wegovy label and an FDA notice.↗↗

This is preserved historical wording.
It is no longer the current profile. Read the canonical profile and its correction notice.
Update · July 29, 2026

We added search aliases that the cited FDA substance-identity record maps to this active ingredient. The profile's status did not change. 3

What this version reported

The cited DailyMed label identifies Semaglutide and contains the product's official indications and warnings. This profile links to the label without restating it as medical guidance.↗

Organizations named in cited records:
  • U.S. National Library of Medicine↗

Sources for this version

  1. 1
    WEGOVY (semaglutide) injection and tablet · SPL version 19 · published 2026-06-30 ↗

    DailyMed · U.S. National Library of Medicine · Official source · Source checked July 22, 2026

  2. 2
    FDA approves higher-dose semaglutide ↗

    U.S. Food and Drug Administration · Official source · Source checked July 22, 2026

  3. 3
    Semaglutide substance identity record ↗

    FDA Global Substance Registration System · Official source · Source checked July 29, 2026